NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
1.38
+0.05 (+3.76%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.33
Open1.33
Bid1.29 x 1000
Ask1.44 x 10000
Day's Range1.30 - 1.42
52 Week Range0.73 - 1.78
Volume19,580,284
Avg. Volume4,553,639
Market Cap428.05M
Beta2.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube17 hours ago

    ETFs with exposure to Novavax, Inc. : December 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novavax, Inc. Here are 5 ETFs with the largest exposure to NVAX-US. Comparing the performance and risk of Novavax, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Options Traders Expect Huge Moves in Novavax (NVAX) Stock
    Zacks3 days ago

    Options Traders Expect Huge Moves in Novavax (NVAX) Stock

    Novavax (NVAX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • 3 Top Stocks Under $10
    Motley Fool6 days ago

    3 Top Stocks Under $10

    Hint: Look to the biotech industry for the best bang for the buck.

  • Market Realist9 days ago

    Exploring the Key Risks Facing Novavax

    Novavax (NVAX) raised $46.0 million through the sale of common stock during the nine months ended September 2017. It raised an additional $3.4 million through the sale of 3.4 million shares through November ...

  • Market Realist9 days ago

    Chart in Focus: Novavax’s Financial Position in 2017

    Novavax (NVAX) generated revenues of $8.4 million in 3Q17 compared with $3.2 million in 3Q16.

  • Market Realist10 days ago

    An Overview of Novavax’s Influenza and Ebola Vaccines

    According to Novavax (NVAX), the value of the influenza vaccine market in developed markets is expected to reach $5.3 billion by 2021–2022 compared with $3.2 billion in 2012–2013.

  • Market Realist10 days ago

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

  • Market Realist10 days ago

    Inside Analysts’ Recommendations for Novavax in November 2017

    A clinical-stage biotech company, Novavax's (NVAX) pipeline includes products for influenza, Ebola virus, and Zika virus. In November, two of seven analysts gave NVAX stock a “strong buy” rating.

  • The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
    Motley Fool10 days ago

    The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November

    Excitement is building for an end-of-year topline data release.

  • 3 Biotech Stocks to Buy in December
    Motley Fool15 days ago

    3 Biotech Stocks to Buy in December

    These great biotech stocks to buy for the holidays come in all sizes -- small-cap, mid-cap, and large-cap.

  • Where Will Novavax, Inc. Be in 5 Years?
    Motley Fool15 days ago

    Where Will Novavax, Inc. Be in 5 Years?

    My prediction: It won't exist. Bad news? Not at all.

  • Capital Cube26 days ago

    ETFs with exposure to Novavax, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novavax, Inc. Here are 5 ETFs with the largest exposure to NVAX-US. Comparing the performance and risk of Novavax, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents27 days ago

    Edited Transcript of NVAX earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 Novavax Inc Earnings Call

  • 3 Reasons Novavax Stock Could Double in 2018
    Motley Fool28 days ago

    3 Reasons Novavax Stock Could Double in 2018

    This biotech's future could be much brighter than its past.

  • Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 14, 2017
    Capital Cubelast month

    Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 14, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Novavax, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Novavax, Inc. (NVAX) Jumps: Stock Rises 8.4%
    Zackslast month

    Novavax, Inc. (NVAX) Jumps: Stock Rises 8.4%

    Novavax, Inc. (NVAX) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

  • Capital Cubelast month

    ETFs with exposure to Novavax, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novavax, Inc. Here are 5 ETFs with the largest exposure to NVAX-US. Comparing the performance and risk of Novavax, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Here's Why the Best Is Yet to Come for Novavax, Inc.
    Motley Foollast month

    Here's Why the Best Is Yet to Come for Novavax, Inc.

    The company's pursuit of two megablockbuster vaccine candidates makes it a viable comeback candidate.

  • Novavax, Inc. :NVAX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cubelast month

    Novavax, Inc. :NVAX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Novavax, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Novavax, Inc. – Sarepta Therapeutics, Inc., Agenus Inc., Emergent BioSolutions Inc., BioCryst Pharmaceuticals, Inc., Novartis AG Sponsored ADR, Achillion Pharmaceuticals, Inc., Pfizer Inc., Celldex Therapeutics, Inc. and GlaxoSmithKline plc ... Read more (Read more...)

  • American City Business Journalslast month

    Novavax in position to seek flu vaccine approval in 2019

    Gaithersburg-based Novavax Inc. could file for regulatory approval to commercialize its flu vaccine candidate as early as 2019. During its third quarter earnings call on Tuesday, CEO Stanley Erck said the company fully enrolled its phase 1/2 clinical trial for its flu vaccine candidate and expects data back by the end of the year. "Assuming that a variety of stars line up, this could lead to a phase 3 pivotal trial this time next year," Erck said.

  • American City Business Journalslast month

    G1 builds out executive team as it eyes important results in 2018

    Roughly four months after naming former GlaxoSmithKline CEO Sir Andrew Witty to its board of directors , Research Triangle Park-based G1 Therapeutics (Nasdaq: GTHX) has a made a pair of additions to its ...

  • Capital Cubelast month

    Novavax, Inc. – Value Analysis (NASDAQ:NVAX) : November 6, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Novavax, Inc. a score of 4. Our analysis is based on comparing Novavax, Inc. with the following peers – Sarepta Therapeutics, Inc., Agenus Inc., Emergent BioSolutions Inc., BioCryst Pharmaceuticals, Inc., Novartis AG Sponsored ADR, Achillion Pharmaceuticals, Inc., Astrazeneca PLC Sponsored ADR, Pfizer Inc., Celldex Therapeutics, Inc. and ... Read more (Read more...)

  • Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 3, 2017
    Capital Cubelast month

    Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : November 3, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Novavax, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Why Novavax Stock Is Soaring Today
    Motley Fool2 months ago

    Why Novavax Stock Is Soaring Today

    Citigroup has high hopes for the little flu vaccine R&D shop.

  • Novavax Stock Upgraded: 3 Things You Need to Know
    Motley Fool2 months ago

    Novavax Stock Upgraded: 3 Things You Need to Know

    'Tis the season for cold and flu stocks.